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Abstract
The diseases of the periodontium are common, aﬀ ecting up to 90% of the global 
inhabitants. The mildest form of periodontal disease presents itself as gingivitis, which 
is reversible and mainly caused by the bacterial biofi lm on teeth and adjacent gingiva. 
Whereas, periodontitis is the moderate to severe form of periodontal disease and 
results in loss of connective tissue and bone support and is one of the major causes 
of adult tooth loss. The ultimate goal of periodontal treatment is to prevent further 
attachment loss and regenerate periodontal supporting tissues. To achieve successful 
periodontal regeneration, various therapeutic strategies are available. Over the past two 
decades, a variety of pharmacological agents have also been studied for regeneration 
of lost periodontal structures. This informational review paper describes the various 
pharmacological agents which are considered important for promoting periodontal 
regeneration.
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Introduction
The structures comprising the periodontium include the gingiva, 
periodontal ligament, cementum and alveolar bone. Several 
diseases aﬀ ect the composition and integrity of periodontal 
structures causing the destruction of the connective tissue (CT) 
matrix and cells, the loss of fi brous attachment and the resorption 
of alveolar bone. These changes often lead to tooth loss.[1]
Therapeutic modalities should aim not only in arresting 
and preventing the progress of periodontal tissue destruction 
but also at reestablishing and regenerating the periodontal 
tissues previously lost to disease. Agents that modulate the 
host response for periodontal repair and regeneration include, 
exogenous growth and diﬀ erentiation factors, attachment factors 
which enhance the normal wound healing response that may be 
of insuﬃ  cient magnitude to promote complete regeneration of 
all attachment structures.[2] Over the past two decades, a variety 
of pharmacological agents have been studied for their possible 
roles in the management of periodontal disease and regeneration 
of its structures.[3]
Host modulation therapy is a treatment approach aiming 
to stabilize or even regenerate the periodontium and reduce 
the destruction of tissues by down-regulating or modifying the 
destructive components of host response and up-regulating the 
protective or regenerative aspects. Restoring a balance between 
the pro-infl ammatory mediators and destructive enzymes with 
that of the anti-infl ammatory mediators and enzyme inhibitors 
is the ultimate purpose of host modulatory therapy [Figure 1]. 
Host modulating agents can be used as adjuncts to scaling and 
root planning (SRP) and can be either systemically administered 
or delivered locally at the intended site. Host modulation with 
chemotherapeutics or drugs is an exciting new adjunctive 
therapeutic option for the management of periodontal 
diseases [4 ]
Non-steroidal Anti-infl ammatory Drugs (NSAID’s)
NSAID’s are a class of drugs that provide analgesic, antipyretic 
and anti-infl ammatory eﬀ ects.
The basis of anti-infl ammatory drugs in periodontal disease 
treatment is related to the control of prostaglandin E2 (PGE2) 
through the inhibition of cyclooxygenase-2 (COX-2) enzyme. 
Higher levels of PGE2 are associated with increased gingival 
infl ammation and alveolar bone loss (Noguchi and Ishikava, 
2007, Reynolds et al., 2007, Tripton et al., 2003).[5]
Arachidonic acid metabolites are pro-infl ammatory 
mediators that have been involved in a wide variety of resorptive 
processes involving bone, including diseases such as chronic 
periodontitis. These mediators can be potentially inhibited by 
NSAIDs, such as aspirin, ibuprofen, fl urbiprofen, and naproxen. 
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NSAIDs inhibit the enzyme COX, thereby preventing the 
production of arachidonic acid metabolites. Use of NSAIDs 
results in decreased levels of pro-infl ammatory mediators that 
may limit the host-mediated alveolar bone destruction observed 
in periodontitis and peri-implant disease [Figure 2].[6]
Oﬀ enbacher et al. (1984) found increasing levels of PGs in 
crevicular fl uid in patients with periodontitis and PGE2 levels 
were 3-fold higher in patients with juvenile periodontitis as 
compared to patients to patients with adult periodontitis.[2]
A double-masked randomized controlled clinical trial was 
conducted in a total of 29 patients with mandibular dental 
implants. Evaluation of healing after dental implant placement 
was done for a period of 3 months following administration of 
100 mg fl urbiprofen, 50 mg fl urbiprofen, or placebo. All the 
patients were evaluated using digital subtraction radiography, 
and they found that, in the high-dose fl urbiprofen group a 
decrease in bone loss was noted after 6 months in implants 
(P < 0.001).[6]
Bisphosphonates (BP’s)
BPs were introduced in 1990 for treatment of osteoporosis 
and osteolytic tumors. They are second group of drugs under 
investigation for their ability to modulate the bone loss and 
prevent bone resorption. They are primarily used to treat 
hypercalcemia, Paget’s disease and osteoporosis. They are 
non-biodegradable analogs of pyrophosphate that have a high 
aﬃ  nity for calcium phosphate crystals and that inhibit osteoclast 
activity.[4]
BPs are drugs that suppress bone turnover, primarily through 
eﬀ ects on osteoclasts, and are commonly prescribed to prevent 
skeletal-related events in malignancy and for benign bone 
diseases such as osteoporosis.[7]
Structure of BP’s
BPs are synthetic molecules with a structure similar to inorganic 
pyrophosphates (Rogers et al., 2000) [Figure 3]. Pyrophosphates 
are endogenous regulators of bone mineralization, which can be 
found naturally in the blood serum, and they have the capacity to 
chelate calcium and to regulate the bone mineralization process 
(Lin, 1996; Rodan, 1998). The biological inhibitory eﬀ ects of 
Figure 1: Th e potential application of host modulation as a therapeutic intervention in the pathogenesis of periodontitis. PMNs: 
Polymorphonuclear leukocytes, CT: Connective tissue; LPS: Lipopolysaccharide[6]
Figure 2: Mechanism of action of non-steroidal anti-infl ammatory 
drugs – they inhibit the synthesis and release the synthesis of 
prostaglandins
Figure 3: Molecular structure of natural pyrophosphate and 
bisphosphonates (BP). Th e central carbon of BP confers stability 
to the molecule and prevents enzymatic acid hydrolysis from 
occurring[8]
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BPs on osteoclast-mediated bone resorption were discovered in 
1968 (Fleisch, 2002). BPs are resistant to enzymatic and chemical 
breakdown, and they present an aﬃ  nity to the mineral phase of 
the bone due to their chelating properties for calcium (Rogers 
et al., 1999). They present a P–C–P molecular structure.[8]
Generations of BP’s
There are three generations of BPs known to exist. The fi rst 
generation has alkyl side chains (etidronate), the second 
generation includes amino-BPs with an amino-terminal side 
chain (alendronate) and the third generation (zoledronate) has 
a cyclic side chain.
Mechanism of action
Several modes of action have been investigated including BP 
mediated inhibition of the development of osteoclasts, induction 
of osteoclastic apoptosis, reduction of activity, prevention of the 
development of osteoclasts from hematopoietic precursors, and 
stimulation of production of an osteoclast inhibitory factor. It 
has also been shown that the BP alendronate caused a rise in 
intracellular calcium levels in an osteoclast-like cell line. This 
fi nding is of great interest since it could suggest the presence of a 
receptor for BPs on osteoclasts.[9]
The proven eﬃ  cacy of BPs to inhibit the osteoclastic bone 
resorption has led to their use in the management of periodontal 
diseases as a host modulating factor in the perspective of 
preventing the alveolar bone loss (Parfi tt, 1994).[8] BPs could 
be used in conjunction with regenerative therapies, and even 
for stimulation of bone growth into and around endosseous 
implants.[9]
Existing literature demonstrate a further benefi t of the systemic 
administration of BPs in addition to mechanical debridement 
compared with mechanical debridement alone. This benefi t is 
mainly the reduction of alveolar bone loss and the preservation of 
the alveolar bone height. On the subject of the clinical parameters, 
some trials failed to show a signifi cant improvement (El-Shinnawi 
and El-Tantawy, 2003), whereas other studies reported that 
BPs supported (in addition to inhibiting alveolar bone loss) the 
periodontal healing, in particular, the reduction of probing pocket 
depth and tooth mobility (Rocha et al., 2001; Takaishi et al., 2001, 
2003; Lane et al., 2005).[8]
Various studies using topically administered BPs have been 
carried out in the recent past due to the serious side-eﬀ ects of 
systemically administered BPs leading to osteonecrosis of the 
jaws and these studies have reported a signifi cant improvement 
in the post-operative percentage of bone defect fi ll, prevention of 
bone resorption as well as the elevated eﬀ ects of locally delivered 
BPs on the osteoconductive and regenerative potential of various 
bone grafts used in the treatment of periodontal diseases.[10]
Statins
Statins are also called as HMG-CoA reductase inhibitors. They 
are a class of drugs which is used to lower the cholesterol levels. 
They mainly act by inhibiting the enzyme HMG-CoA reductase, 
which plays a central role in the production of cholesterol in 
the liver, and contributes to produce about 70% of total body 
cholesterol.
Molecular structure of statins[11]
Statin contains a hexahydronaphthalene ring with two major 
side chains, viz. dimethylbutyrate ester and a second one, which 
contains a hydroxyacid [Figure 4]. The hydroxyacid of the 
second chain forms a six-membered analog of the intermediate 
compound in the HMG-CoA reductase reaction, which is the 
rate-limiting step in the mevalonate pathway. As a result of its 
similarity to the compound HMG-CoA, statin is a reversible 
competitive inhibitor of the enzyme HMG-CoA reductase. 
The reaction catalyzed by HMG-CoA reductase and inhibited 
by simvastatin is the conversion of HMG-CoA to a compound 
called mevalonate via an intermediate. Simvastatin like the 
other statins is thus an inhibitor of the mevalonate pathway and 
consequently cholesterol synthesis.
Statins have potential anti-infl ammatory eﬀ ect. Statins 
in systemic and local application enhance osteoblastic 
diﬀ erentiation and bone formation by upregulating bone 
morphogenic proteins and by blocking the intermediate 
metabolites of the mevalonate pathway. Because of these eﬀ ects, 
statins can be used in treating periodontal disease and promoting 
periodontal regeneration.[12]
Additionally, it has been observed that statins like simvastatin, 
atorvastatin, and cerivastatin markedly enhance gene expression 
for vascular endothelial growth factor, which is involved in 
the process of endochondral bone formation and stimulates 
osteoblastic diﬀ erentiation leading to new bone formation. It has 
also been suggested that statin use was associated with decreased 
tooth loss in chronic periodontitis patients.[11]
An in vitro study was conducted by Yazawa et al., using 
periodontal ligament cells obtained from human teeth and it was 
seen that simvastatin signifi cantly enhanced cell proliferation 
and metabolism dose-dependently after 24 h. Simvastatin 
concentrations of 10-8 and 10-7 M showed the maximum eﬀ ect 
and after 7 days, alkaline phosphatase activity was boosted 
dose-dependently and at a concentration of 10-8 M showed the 
maximum eﬀ ect.[13]
Pradeep et al., recently in a clinical study reported a greater 
reduction in the gingival index and probing depth (PD) at 
Figure 4: Molecular structure of statins
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sites treated with SRP and locally delivered simvastatin as 
compared to SRP plus placebo in human subjects with chronic 
periodontitis. In addition, more clinical attachment level gain as 
well as signifi cant intrabony defect fi ll was seen in the simvastatin-
treated individuals.[14]
Antimicrobial Agents
Antiproteinases used in the treatment of periodontitis are 
tetracyclines. Along with antimicrobial activity, tetracycline 
agents have the ability to inhibit neutrophils, osteoclasts, and 
matrix metalloproteinases (MMPs) that appear to be involved 
in the destruction of the periodontium. Tetracyclines have an 
anti-infl ammatory action and may be bone-sparing through 
inhibition of osteoclasts. Doxycycline is the most studied and 
strongest collagenase inhibitor of the used tetracyclines.[6]
MMP is considered to be the key initiators of collagen 
degradation thus contributing to bone resorption in infl ammatory 
diseases. Subantimicrobial doses of doxycycline are a known 
MMP inhibitors and hence inhibits bone resorption.[15]
Recently, a formulation containing a sub antimicrobial dose of 
doxycycline (Doxycycline hyclate 20 mg; Periostat, CollaGenex, 
Pharmaceuticals Newton PA) is FDA approved and ADA 
accepted. It is indicated as an adjunct to SRP in the treatment 
of chronic periodontitis. It has been evaluated as 20 mg taken 
twice daily for up to 9 months of continuous dosing in clinical 
trials. The 20 mg twice per day dose exerts its therapeutic eﬀ ect 
by enzyme, cytokine, and osteoclast inhibition, rather than by 
any antibiotic eﬀ ect.[4]
Golub et al. (1990) studied the eﬀ ects of low dose 
doxycycline therapy on the gingival crevicular fl uid in human 
subjects. A 2 weeks regimen of these capsules (each containing 
20 or 30 mg of the drug) signifi cantly reduced the excess host 
collagenase activity in extracts of infl amed gingival tissues. This 
eﬀ ect was not reduced in placebo, treated patients who had adult 
periodontitis.[2]
Chemically modifi ed tetracyclines tackle periodontitis by 
prevention of breakdown of CT. They mainly act by inhibition 
of metal-dependent MMPs, scavenging the reactive oxygen 
species, enhancing the attachment of fi broblasts and CTs to 
the tooth surface, suppression of neutrophils, inhibition of 
generation of metabolites of arachidionic acid by blocking the 
PGE2 synthesis and phospholipase A2, and hence regenerating 
lost periodontium.[16]
Azithromycin is an azalide, a subclass of macrolide antibiotic 
used extensively in medicine for the treatment of a wide 
range of bacterial infections. It inhibits some Gram-positive 
bacteria, some Gram-negative bacteria, and many atypical 
including few common periodontopathogens. Apart from 
their antibiotic properties they also have well-documented 
immune-modulating/anti-infl ammatory eﬀ ects. Azithromycin 
is signifi cantly concentrated in macrophages, neutrophils and 
particularly in the fi broblasts; all of these cells play a major 
role in the pathogenesis of most periodontal diseases. Use of 
azithromycin in the treatment of advanced periodontal diseases 
has shown signifi cant results. Azithromycin could also have 
a triple role in the resolution and treatment of periodontal 
diseases such as anti-infl ammatory activity, suppressing 
periodontopathogens and healing through persistence at low 
levels fi broblasts and macrophages in periodontal tissues, even 
after a single course of three tablets.[17]
Hormonal Therapy
Parathyroid hormone (PTH)
The mechanism of the PTHs action is complex and involves 
pathways linked to common signaling peptides that aﬀ ect 
osteoblast gene transcription. In vitro studies, in vivo experiments, 
and clinical trials demonstrated that intermittent PTH 1-34 
administration induced anabolic eﬀ ects on cancellous and 
cortical bone, enhanced bone mass, and increased mechanical 
bone strength.[18]
Estrogen
The relationship between estrogens and periodontal tissues was 
studied mainly for its possible implication in the infl ammatory 
process, with a clear demonstration that estrogens do not 
increase infl ammation. Most cells in the periodontium 
(fi broblasts, endothelial cells, epithelial gingival cells, osteoclasts, 
and osteoblasts) express estrogen receptors α and β. It is well 
known that estrogens decrease bone resorption and have a 
positive eﬀ ect on bone formation.[19] Treatment with estrogens 
clearly inhibits bone loss as well as bone turnover and increases 
bone mineral density. There is substantial evidence that estrogen 
inhibits both osteoclast activity and diﬀ erentiation by regulating 
the production of stimulatory and inhibitory cytokines by 
osteoblasts and monocytes. Various reports also have linked 
estrogen defi ciency and osteoporosis to increased oral bone 
resorption, attachment loss, and tooth loss.[20]
Selective estrogen receptor modulators (SERMs)
The discovery of the agents able to exert full or partial estrogen 
eﬀ ects on various tissues led to the development of a new class of 
drugs known as SERMs. The mechanism by which SERMs inhibit 
bone resorption is likely to be the same as estrogen’s mechanism, 
by blocking production of cytokines that promote osteoclast 
diﬀ erentiation and by promoting osteoclast apoptosis.[20]
Teriparatide
It is a recombinant form of PTH consisting of the fi rst 34 amino 
acids of PTH. Since it is identical to a portion of human PTH, 
it is known as biosynthetic human PTH. It is a highly potent 
anabolic (i.e. bone growing) agent and most commonly used in 
the treatment of osteoporosis.
The biological actions of teriparatide and PTH are mainly 
activated through specifi c, G-protein-dependent, high-aﬃ  nity 
membrane cell-surface receptors. These receptors are mainly 
demonstrated in osteoblasts and renal tubular cells. It has been 
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demonstrated that ligand binding promotes a cascade that 
energize protein kinase-1, protein kinase C, cyclic adenosine 
monophosphate (cAMP) and phospholipase C. The activation 
of these pathways results in an up-regulation of the number of 
active osteoblasts, a down-regulation in osteoblast apoptosis 
and probably, increase of bone lining cells as newly formed 
osteoblasts, thereby enhancing bone strength, structural 
integrity, mass and diameter, as well as increasing serum and 
urinary levels of markers of bone resorption and formation. 
Individuals treated with teriparatide have shown up-regulation 
of basic fi broblast growth factor 2 (bFGF-2). Since bFGF-2 
enhances the proliferation and diﬀ erentiation of osteoblast 
progenitor cells, this cytokine could play a major role in the bone 
formative response to teriparatide therapy.[3]
Miscellaneous Drugs
Anti-arthritic medications
Anti-arthritic medications have also been suggested to be of 
potential benefi t, but their mechanism of action is unclear at 
this time. However, gold salts like aurofi n, aurothioglucose, 
aurothiomalate, sometimes used to treat arthritis have been 
shown to accumulate in gingiva and gingival crevicular fl uid, and 
may produce an antibacterial and anti-infl ammatory at the site of 
periodontal infections (Freeman et al. 1984, Polson et al. 1984).[21]
Cimetidine
Cimetidine is a powerful H2 (Histamine) receptor antagonist, 
and hence eliminates histamine’s inhibitory eﬀ ects on immune 
response, thereby acting as a modulator of infl ammation and 
immunity by inhibiting neutrophil chemotaxis and superoxide 
production, increasing cAMP levels and down-regulating 
cytokines. Topically active cimetidine is a potent inhibitor of 
periodontal infl ammation caused mainly by P. gingivalis, this 
morphologic and histologic evidence was provided by Hasturk 
et al. (2006) and they also showed that it can arrest and/or 
prevent tissue destruction and infl uence cell populations present 
in the infl ammatory cell infi ltrate.[10]
Hyaluronic acid (HA)
HA is a polysaccharide (glycosaminoglycan), also known as 
hyaluronan or hyaluronate, it has a high molecular weight and 
has a major role in the activity of extracellular matrices, including 
those of non-mineralized and mineralized periodontal tissues. 
It contributes signifi cantly to cell migration, proliferation 
and tissue hydrodynamics and is a vital component of the 
extracellular matrix. Hyaluronan is also produced in the 
presence of endotoxins by fi broblasts, and it plays a crucial anti-
infl ammatory role by facilitating healing and inhibition of tissue 
destruction.[22]
Ballini et al. in a study found that there were good capabilities 
in accelerating new bone formation in the infra-bony defects 
when autologous bone was combined with an esterifi ed 
low-molecular HA preparation.[23]
HA shares bone induction characteristics with bone 
morphogenetic protein-2 and osteopontin which are majorly 
osteogenic in nature.[24] It accelerates the bone regeneration 
via proliferation, successive diﬀ erentiation and chemotaxis of 
mesenchymal cells.
Another study was conducted by Engström et al. to 
investigate the anti-infl ammatory eﬀ ect and the eﬀ ect on bone 
regeneration of Hyaluronan in surgical and non-surgical groups. 
On radiographic examination, in the non surgical group there 
was no statistical diﬀ erence, whereas the reduction in the bone 
height was seen for both groups after scaling. PD signifi cantly 
reduced after the surgical treatment as well as after SRP.[25]
Conclusion
Periodontopathic microorganisms and destructive host response 
are involved in the initiation and progression of periodontal 
disease, and there are situations in which conventional therapy 
does not always achieve the desired clinical outcome.
The improved understanding of the host bacterial interactions 
and the host immune-infl ammatory response leading to 
periodontal tissue destruction has led to the development of 
Host modulation therapy. The risk/benefi t ratio concerned to 
the use of host modulating agents are yet to be established even 
though the usefulness and eﬃ  cacy of these agents have been 
demonstrated by many clinical trials and have been approved 
by FDA for the management of periodontitis. Furthermore, 
continuous research in this fi eld and Multicenter clinical trials 
are necessary to completely evaluate the benefi ts, usefulness and 
the risks associated with the long-term administration of these 
agents and also to enable planning of customized treatment 
approach for periodontal diseases by targeting infl ammatory 
host response.
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